Literature DB >> 35325614

Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.

Jong-Min Lee1, Yuan Huang2, Michael Orth3, Tammy Gillis4, Jacqueline Siciliano4, Eunpyo Hong4, Jayalakshmi Srinidhi Mysore4, Diane Lucente4, Vanessa C Wheeler5, Ihn Sik Seong5, Zachariah L McLean1, James A Mills6, Branduff McAllister7, Sergey V Lobanov7, Thomas H Massey7, Marc Ciosi8, G Bernhard Landwehrmeyer9, Jane S Paulsen10, E Ray Dorsey11, Ira Shoulson11, Cristina Sampaio12, Darren G Monckton8, Seung Kwak12, Peter Holmans7, Lesley Jones7, Marcy E MacDonald1, Jeffrey D Long6, James F Gusella13.   

Abstract

Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage. The largest studies have been limited to HD individuals with a rater-estimated age at motor onset. To capitalize on the wealth of phenotypic data in several large HD natural history studies, we have performed algorithmic prediction by using common motor and cognitive measures to predict age at other disease landmarks as additional phenotypes for GWASs. Combined with imputation with the Trans-Omics for Precision Medicine reference panel, predictions using integrated measures provided objective landmark phenotypes with greater power to detect most modifier loci. Importantly, substantial differences in the relative modifier signal across loci, highlighted by comparing common modifiers at MSH3 and FAN1, revealed that individual modifier effects can act preferentially in the motor or cognitive domains. Individual components of the DNA maintenance modifier mechanisms may therefore act differentially on the neuronal circuits underlying the corresponding clinical measures. In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7. These findings indicate that broadened discovery and characterization of HD genetic modifiers based on additional quantitative or qualitative phenotypes offers not only the promise of in-human validated therapeutic targets but also a route to dissecting the mechanisms and cell types involved in both the somatic instability and toxicity components of HD pathogenesis.
Copyright © 2022 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAG repeat; DNA maintenance; DNA repair; Huntington disease; age at onset; disease modification; genetic modifier; polyglutamine disease; somatic expansion; trinucleotide repeat

Mesh:

Substances:

Year:  2022        PMID: 35325614      PMCID: PMC9118113          DOI: 10.1016/j.ajhg.2022.03.004

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.043


  43 in total

1.  Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.

Authors:  Michael Orth; O J Handley; C Schwenke; S Dunnett; E J Wild; S J Tabrizi; G B Landwehrmeyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-11-19       Impact factor: 10.154

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  Identification of symbol digit modality test score extremes in Huntington's disease.

Authors:  Ulrike Braisch; Rainer Muche; Dietrich Rothenbacher; Georg Bernhard Landwehrmeyer; Jeffrey D Long; Michael Orth
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-20       Impact factor: 3.568

4.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes.

Authors:  J P Warner; L H Barron; D J Brock
Journal:  Mol Cell Probes       Date:  1993-06       Impact factor: 2.365

5.  Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease.

Authors:  L Djoussé; B Knowlton; M Hayden; E W Almqvist; R Brinkman; C Ross; R Margolis; A Rosenblatt; A Durr; C Dode; P J Morrison; A Novelletto; M Frontali; R J A Trent; E McCusker; E Gómez-Tortosa; D Mayo; R Jones; A Zanko; M Nance; R Abramson; O Suchowersky; J Paulsen; M Harrison; Q Yang; L A Cupples; J F Gusella; M E MacDonald; R H Myers
Journal:  Am J Med Genet A       Date:  2003-06-15       Impact factor: 2.802

6.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

7.  A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study.

Authors:  Jian-Liang Li; Michael R Hayden; Elisabeth W Almqvist; Ryan R Brinkman; Alexandra Durr; Catherine Dodé; Patrick J Morrison; Oksana Suchowersky; Christopher A Ross; Russell L Margolis; Adam Rosenblatt; Estrella Gómez-Tortosa; David Mayo Cabrero; Andrea Novelletto; Marina Frontali; Martha Nance; Ronald J A Trent; Elizabeth McCusker; Randi Jones; Jane S Paulsen; Madeline Harrison; Andrea Zanko; Ruth K Abramson; Ana L Russ; Beth Knowlton; Luc Djoussé; Jayalakshmi S Mysore; Suzanne Tariot; Michael F Gusella; Vanessa C Wheeler; Larry D Atwood; L Adrienne Cupples; Marie Saint-Hilaire; Jang-Ho J Cha; Steven M Hersch; Walter J Koroshetz; James F Gusella; Marcy E MacDonald; Richard H Myers
Journal:  Am J Hum Genet       Date:  2003-08-01       Impact factor: 11.025

8.  Genome-wide efficient mixed-model analysis for association studies.

Authors:  Xiang Zhou; Matthew Stephens
Journal:  Nat Genet       Date:  2012-06-17       Impact factor: 38.330

9.  MAGMA: generalized gene-set analysis of GWAS data.

Authors:  Christiaan A de Leeuw; Joris M Mooij; Tom Heskes; Danielle Posthuma
Journal:  PLoS Comput Biol       Date:  2015-04-17       Impact factor: 4.475

10.  MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.

Authors:  Michael Flower; Vilija Lomeikaite; Marc Ciosi; Sarah Cumming; Fernando Morales; Kitty Lo; Davina Hensman Moss; Lesley Jones; Peter Holmans; Darren G Monckton; Sarah J Tabrizi
Journal:  Brain       Date:  2019-06-19       Impact factor: 13.501

View more
  2 in total

1.  Inherited HTT CAG repeat length does not have a major impact on Huntington disease duration.

Authors:  Jong-Min Lee; Marcy E MacDonald; James F Gusella
Journal:  Am J Hum Genet       Date:  2022-07-07       Impact factor: 11.043

Review 2.  A Glimpse of Molecular Biomarkers in Huntington's Disease.

Authors:  Silvia Martí-Martínez; Luis M Valor
Journal:  Int J Mol Sci       Date:  2022-05-12       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.